Subcutaneous Fluid Administration
Amphadase® is indicated as an adjuvant in subcutaneous
fluid administration for achieving hydration.
Dispersion And Absorption Of Injected Drugs
Amphadase® is indicated as an adjuvant to increase the
dispersion and absorption of other injected drugs.
Amphadase® is indicated as an adjunct in subcutaneous
urography for improving resorption of radiopaque agents.
DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for
particulate matter and discoloration prior to administration, whenever solution
and container permit.
Subcutaneous Fluid Administration (Hypodermoclysis )
Insert needle with aseptic precautions. With tip lying
free and movable between skin and muscle, begin clysis; fluid should start in
readily without pain or lump. Then inject Amphadase® (hyaluronidase injection)
into rubber tubing close to needle.
An alternate method is to inject Amphadase® under skin
prior to clysis. 150 U will facilitate absorption of 1,000 mL or more of
solution. As with all parenteral fluid therapy, observe effect closely, with
same precautions for restoring fluid andelectrolyte balance as in intravenous
injections. The dose, the rate of injection, and the type of solution (saline,
glucose, Ringer's, etc.) must be adjusted carefully to the individual patient.
When solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia
may occur. This may be prevented by using solutions containing adequate amounts
of inorganic electrolytes and/or controlling the volume and speed of
administration. Amphadase® may be added to small volumes of solution (up to 200
mL), such as small clysis for infants or solutions of drugs for subcutaneous
injection. For infants and children less than 3 years old, the volume of a
single clysis should be limited to 200 mL; and in premature infants or during
the neonatal period, the daily dosage should not exceed 25 mL/kg of body
weight; the rate of administration should not be greater than 2 mL per minute.
For older patients, the rate and volume of administration should not exceed
those employed for intravenous infusion.
Absorption And Dispersion Of Injected Drugs
Absorption and dispersion of other injected drugs may be
enhanced by adding 50-300 Units, most typically 150 U hyaluronidase, to the
The subcutaneous route of administration of urographic
contrast media is indicated when intravenous administration cannot be
successfully accomplished, particularly in infants and small children. With the
patient prone, 75 U of Amphadase® (hyaluronidase injection) is injected
subcutaneously over each scapula, followed by injection of the contrast medium
at the same sites.
Dosage Forms And Strengths
150 USP units/mL single dose vials
Storage And Handling
Amphadase® (hyaluronidase injection) is supplied sterile
as 150 USP units of hyaluronidase per mL in a 2 mL single-use glass vial with a
gray rubber stopper and aluminum flip-off seal.
NDC 0548-9090-10, 1 mL vial, 10 vials/carton.
Store unopened in a refrigerator at 2° to 8°C (36° to
Amphastar Pharmaceuticals , Inc., Rancho Cucamonga, CA
91730, U.S.A. Revised: May 2014